Early growth response-1 gene: Potential radiation response gene marker in prostate cancer

Mansoor M. Ahmed, Damodaran Chendil, Subodh Lele, Kolaparthi Venkatasubbarao, Swatee Dey, Marylynn Ritter, Randall G. Rowland, Mohammed Mohiuddin

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

This study was undertaken to determine whether the transcription factor EGR-1 expression: (1) in the primary tumor, correlates with radiation response in terms of complete local tumor control with no evidence of disease or recurrence and no evidence of metastasis; (2) in the postirradiated biopsies correlates with residual tumor; and (3) correlates with the expression of Egr-1 target genes such as TP53, pRB, and Bax. The authors analyzed: (1) 25 pretreated surgically resected paraffin-embedded primary adenocarcinomas of the prostate for the presence of EGR-1 expression and mutation, and correlated this with clinical endpoints such as serum prostate-specific antigen levels and current clinical status; (2) 27 postirradiated biopsies of prostate for the presence of EGR-1 expression, and correlated these findings to the residual tumor status; and (3) 12 prospective prostate tumor specimens for EGR-1 expression and its target genes. EGR-1 expression was determined by immunohistochemistry and mutations were screened in two regions of the Egr-1 gene (trinucleotide AGC repeats in transactivation domain [TD] and poly A tract in 3′UTR) by polymerase chain reaction-single strand conformational polymorphism analysis. Of 25 patients, 18 patients showed expression of EGR-1. EGR-1 overexpression correlated with treatment failure. No correlation with EGR-1 overexpression and its target genes was found, which may indirectly suggest that overexpressed EGR-1 may lack transactivation function. In summary, EGR-1 overexpression in the mutant form may provide an indication of clinical failure (local recurrence or metastasis).

Original languageEnglish (US)
Pages (from-to)500-505
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume24
Issue number5
DOIs
StatePublished - Oct 23 2001

Fingerprint

Prostatic Neoplasms
Radiation
Prostate
Residual Neoplasm
Growth
Transcriptional Activation
Genes
Early Growth Response Transcription Factors
Neoplasm Metastasis
Biopsy
Trinucleotide Repeats
Recurrence
Neoplasms
Mutation
Poly A
Prostate-Specific Antigen
Treatment Failure
Paraffin
Adenocarcinoma
Immunohistochemistry

Keywords

  • Apoptosis
  • EGR-1
  • Gene overexpression
  • Prostate cancer
  • Radiation
  • Radiation resistance

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Early growth response-1 gene : Potential radiation response gene marker in prostate cancer. / Ahmed, Mansoor M.; Chendil, Damodaran; Lele, Subodh; Venkatasubbarao, Kolaparthi; Dey, Swatee; Ritter, Marylynn; Rowland, Randall G.; Mohiuddin, Mohammed.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 24, No. 5, 23.10.2001, p. 500-505.

Research output: Contribution to journalArticle

Ahmed, Mansoor M. ; Chendil, Damodaran ; Lele, Subodh ; Venkatasubbarao, Kolaparthi ; Dey, Swatee ; Ritter, Marylynn ; Rowland, Randall G. ; Mohiuddin, Mohammed. / Early growth response-1 gene : Potential radiation response gene marker in prostate cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2001 ; Vol. 24, No. 5. pp. 500-505.
@article{6b010988d1c044209e7fff087742c856,
title = "Early growth response-1 gene: Potential radiation response gene marker in prostate cancer",
abstract = "This study was undertaken to determine whether the transcription factor EGR-1 expression: (1) in the primary tumor, correlates with radiation response in terms of complete local tumor control with no evidence of disease or recurrence and no evidence of metastasis; (2) in the postirradiated biopsies correlates with residual tumor; and (3) correlates with the expression of Egr-1 target genes such as TP53, pRB, and Bax. The authors analyzed: (1) 25 pretreated surgically resected paraffin-embedded primary adenocarcinomas of the prostate for the presence of EGR-1 expression and mutation, and correlated this with clinical endpoints such as serum prostate-specific antigen levels and current clinical status; (2) 27 postirradiated biopsies of prostate for the presence of EGR-1 expression, and correlated these findings to the residual tumor status; and (3) 12 prospective prostate tumor specimens for EGR-1 expression and its target genes. EGR-1 expression was determined by immunohistochemistry and mutations were screened in two regions of the Egr-1 gene (trinucleotide AGC repeats in transactivation domain [TD] and poly A tract in 3′UTR) by polymerase chain reaction-single strand conformational polymorphism analysis. Of 25 patients, 18 patients showed expression of EGR-1. EGR-1 overexpression correlated with treatment failure. No correlation with EGR-1 overexpression and its target genes was found, which may indirectly suggest that overexpressed EGR-1 may lack transactivation function. In summary, EGR-1 overexpression in the mutant form may provide an indication of clinical failure (local recurrence or metastasis).",
keywords = "Apoptosis, EGR-1, Gene overexpression, Prostate cancer, Radiation, Radiation resistance",
author = "Ahmed, {Mansoor M.} and Damodaran Chendil and Subodh Lele and Kolaparthi Venkatasubbarao and Swatee Dey and Marylynn Ritter and Rowland, {Randall G.} and Mohammed Mohiuddin",
year = "2001",
month = "10",
day = "23",
doi = "10.1097/00000421-200110000-00017",
language = "English (US)",
volume = "24",
pages = "500--505",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Early growth response-1 gene

T2 - Potential radiation response gene marker in prostate cancer

AU - Ahmed, Mansoor M.

AU - Chendil, Damodaran

AU - Lele, Subodh

AU - Venkatasubbarao, Kolaparthi

AU - Dey, Swatee

AU - Ritter, Marylynn

AU - Rowland, Randall G.

AU - Mohiuddin, Mohammed

PY - 2001/10/23

Y1 - 2001/10/23

N2 - This study was undertaken to determine whether the transcription factor EGR-1 expression: (1) in the primary tumor, correlates with radiation response in terms of complete local tumor control with no evidence of disease or recurrence and no evidence of metastasis; (2) in the postirradiated biopsies correlates with residual tumor; and (3) correlates with the expression of Egr-1 target genes such as TP53, pRB, and Bax. The authors analyzed: (1) 25 pretreated surgically resected paraffin-embedded primary adenocarcinomas of the prostate for the presence of EGR-1 expression and mutation, and correlated this with clinical endpoints such as serum prostate-specific antigen levels and current clinical status; (2) 27 postirradiated biopsies of prostate for the presence of EGR-1 expression, and correlated these findings to the residual tumor status; and (3) 12 prospective prostate tumor specimens for EGR-1 expression and its target genes. EGR-1 expression was determined by immunohistochemistry and mutations were screened in two regions of the Egr-1 gene (trinucleotide AGC repeats in transactivation domain [TD] and poly A tract in 3′UTR) by polymerase chain reaction-single strand conformational polymorphism analysis. Of 25 patients, 18 patients showed expression of EGR-1. EGR-1 overexpression correlated with treatment failure. No correlation with EGR-1 overexpression and its target genes was found, which may indirectly suggest that overexpressed EGR-1 may lack transactivation function. In summary, EGR-1 overexpression in the mutant form may provide an indication of clinical failure (local recurrence or metastasis).

AB - This study was undertaken to determine whether the transcription factor EGR-1 expression: (1) in the primary tumor, correlates with radiation response in terms of complete local tumor control with no evidence of disease or recurrence and no evidence of metastasis; (2) in the postirradiated biopsies correlates with residual tumor; and (3) correlates with the expression of Egr-1 target genes such as TP53, pRB, and Bax. The authors analyzed: (1) 25 pretreated surgically resected paraffin-embedded primary adenocarcinomas of the prostate for the presence of EGR-1 expression and mutation, and correlated this with clinical endpoints such as serum prostate-specific antigen levels and current clinical status; (2) 27 postirradiated biopsies of prostate for the presence of EGR-1 expression, and correlated these findings to the residual tumor status; and (3) 12 prospective prostate tumor specimens for EGR-1 expression and its target genes. EGR-1 expression was determined by immunohistochemistry and mutations were screened in two regions of the Egr-1 gene (trinucleotide AGC repeats in transactivation domain [TD] and poly A tract in 3′UTR) by polymerase chain reaction-single strand conformational polymorphism analysis. Of 25 patients, 18 patients showed expression of EGR-1. EGR-1 overexpression correlated with treatment failure. No correlation with EGR-1 overexpression and its target genes was found, which may indirectly suggest that overexpressed EGR-1 may lack transactivation function. In summary, EGR-1 overexpression in the mutant form may provide an indication of clinical failure (local recurrence or metastasis).

KW - Apoptosis

KW - EGR-1

KW - Gene overexpression

KW - Prostate cancer

KW - Radiation

KW - Radiation resistance

UR - http://www.scopus.com/inward/record.url?scp=0034797007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034797007&partnerID=8YFLogxK

U2 - 10.1097/00000421-200110000-00017

DO - 10.1097/00000421-200110000-00017

M3 - Article

C2 - 11586104

AN - SCOPUS:0034797007

VL - 24

SP - 500

EP - 505

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 5

ER -